Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
about
Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cellsmTOR-Dependent Cell Proliferation in the Brain.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
P2860
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@ast
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@en
type
label
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@ast
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@en
prefLabel
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@ast
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@en
P2093
P2860
P1476
Vandetanib plus sirolimus in a ...... nd dose expansion cohort study
@en
P2093
Andrew D Norden
Andrew S Chi
April F Eichler
Daniel Yang
Elizabeth R Gerstner
Fred H Hochberg
Jan Drappatz
Milan G Chheda
Patrick Y Wen
Rameen Beroukhim
P2860
P2888
P304
P356
10.1007/S11060-014-1680-2
P577
2014-12-13T00:00:00Z